Radiopaque liquid embolic composition comprising a radiopaque polymer

Abstract

To provide a polymer having sufficient radiopacity for observation under X-ray.SOLUTION: A hydrophilic polymer comprising a pendant group of formula I, wherein W is independently selected from -OH, -COOH, -SO3H, -OPO3H2, -O-(C1-4 alkyl), -O-(C1-4 alkyl)OH, -O-(C1-4 alkyl)R2, -O-(C2H5O)qR1-(C=O)-O-C1-4 alkyl, and -O-(C=O)C1-4 alkyl; X is either a bond or a linking group having 1 to 8 carbon atoms and optionally 1 to 4 heteroatoms selected from O, N, and S; and G is a coupling group through which the group of formula I is coupled to the polymer.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to radiopaque polymers and, more particularly, to their use in the manufacture of medical devices and medical procedures. The present invention relates to radiopaque polymers that are particularly useful in the field of therapeutic embolization. [Background technology]

[0002] Therapeutic embolization is a minimally invasive procedure in which materials are introduced into blood vessels to create a blockage in order to slow or stop blood flow. Typically, such materials are delivered via a microcatheter that is advanced from a peripheral location, such as the leg or wrist, to the target site. This approach has been useful in treating conditions such as gastrointestinal bleeding, arteriovenous malformations, hypervascular malignant tumors such as hepatocellular carcinoma, benign growths such as uterine fibroids, and more recently, benign prostatic hyperplasia (BPH), among others.

[0003] Biocompatible microspheres are useful embolic agents because they can be easily delivered to the target site and provided in a defined size range for more predictable embolization depending on vessel size. Liquid emboli, delivered as liquids, have also found utility in several areas using materials that gel, solidify, or precipitate in situ. Some such systems rely on polymer formation or in situ gelation, while others rely on delivery in organic solvents that rapidly dissipate into the blood, leaving the embolic material behind. Liquid emboli have the added advantage of conforming to the vessel wall and, depending on their deposition characteristics, typically forming uniform emboli rather than discrete spheres. Embolic materials are typically synthetic or natural polymers, selected to provide favorable properties such as biocompatibility, density, compressibility, flowability, drug loading, and ease of catheter delivery. Other important properties for liquid emboli include intravascular flow characteristics, the rate and predictability of deposition, and the robustness of the emboli.

[0004] Radiopaque polymer microspheres with iodinated groups covalently attached to the polymer backbone have been proposed (e.g., Patent Document 1). The iodinated groups allow these materials to be visualized using X-ray-based techniques, but the presence of iodine can lead to suboptimal handling characteristics, such as insufficient drug loading, poor compressibility, and reduced suspension times.

[0005] Radiopaque liquid emboli having iodinated groups attached to the polymer backbone have also been described (e.g., U.S. Patent No. 5,929,393). However, similar to polymer microspheres, the presence of iodine alters the physical properties of the polymer, resulting in poor handling characteristics, such as unpredictable and rapid precipitation, polymer "stringing," and other unfavorable handling properties. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] International Publication No. 2015 / 033092 [Patent Document 2] International Publication No. 2011 / 110589 Summary of the Invention [Problem to be solved by the invention]

[0007] It would therefore be desirable to provide improved iodinated polymers that are sufficiently radiopaque for visibility on X-ray, yet have improved ease of use. [Means for solving the problem]

[0008] The present inventors have determined that one or more of these problems can be addressed by the polymers described herein. Thus, in a first aspect, the present invention provides a hydrophilic polymer comprising a pendant group of formula I:

[0009] [ka]

[0010] Here, W is -OH, -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl), -O-(C 1~4 alkyl)OH, -O-(C 1~4 alkyl)R 2 , -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alkyl and -O-(C=O)C 1~4 alkyl; alternatively, W can be a zwitterionic group of formula -BZ; wherein -OH, -COOH, -OPO3H2 and -SO3H may be in the form of a pharmaceutically acceptable salt; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N, and S; G is a linking group that attaches the group of formula I to the polymer and is selected from ethers, esters, amides, carbonates, carbamates, 1,3 dioxolones, and 1,3 dioxanes; R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, q is an integer from 1 to 4, n is an integer from 1 to 4, p is an integer from 1 to 3; n+p is 2 to 5, wherein -COOH, -OPOH and -SOH, and phenolic -OH may be in the form of a pharmaceutically acceptable salt; W is a zwitterionic group of formula -BZ, where B is a bond or a linear or branched alkanediyl, oxyalkylene, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally bearing one or more fluorine substituents, and Z is a zwitterionic ammonium, phosphonium, or ester group such as a sulfonium phosphate or phosphonate.

[0011] The group Z is zwitterionic and contains an ammonium, phosphonium, or sulfonium group as the cationic moiety. Preferably, the cation is an ammonium group. The anion of the zwitterion is a phospho moiety, which is typically a phosphate diester or phosphonate ester-based moiety. Typically, in Z, the anion is closer to B than the cation (non-phosphobetaines). However, in some zwitterions, the cation is closer to the B group than the anion (hereinafter referred to as phosphobetaines).

[0012] Preferably, in non-phosphobetaines, Z is a group of general formula II.

[0013] [ka]

[0014] Here, the same or different part A 3 and A 4 is —O, —S, —NH— or a valence bond, preferably —O—; W + is a cationic group from the group consisting of ammonium, phosphonium and sulfonium, and preferably C 1~12 and a group linking the anionic and cationic moieties which is an alkanediyl group, preferably W 1+ teeth, -W 2 -N + R 4 3,-W 2 -P + R 5 3,-W 2 -S + R 5 2, or -W2 -Het + is the basis of W 2 is one or more, preferably alkanediyl of 2 to 6 carbon atoms, optionally having one or more ethylenically unsaturated double or triple bonds, disubstituted aryl(arylene), alkylenearylene, arylenealkylene, or alkylenearylalkylene, and these groups W 1 optionally contains one or more fluorine substituents and / or one or more functional groups, and the group R 4 are the same or different and each is hydrogen or alkyl of 1 to 4 carbon atoms, preferably methyl, or aryl such as phenyl. Alternatively, two groups R 4 together with the nitrogen atom to which they are attached form an aliphatic heterocycle containing 5 to 7 atoms. Alternatively, three groups R 4 together with the nitrogen atom to which they are attached form a fused ring structure containing 5 to 7 atoms in each ring, optionally containing one or more groups R 4 is substituted with a hydrophilic functional group. 5 The groups may be the same or different, and each R 4 OR 4 is a group, and R 4 is as defined above. Het is an aromatic nitrogen, phosphorus, or sulfur, preferably nitrogen, containing ring, such as pyridine.

[0015] Z is W + W 1 N + R 4 Compounds of the general formula 3 can be made as described in WO 93 / 01221. Phosphonium and sulfonium analogues are described in WO 95 / 20407 and WO 9416749. Of the compounds where W is -BZ, Z is W 1+ W 2 N+R 4Preferred are compounds of the general formula such that: 3. Generally, the Z group of formula II has the preferred general formula III.

[0016] [ka]

[0017] where the group R 6 are the same or different, and each is hydrogen or C 1~4 alkyl, m is 1 to 4, and preferably a group R 6 are the same and are preferably methyl. A particularly preferred example of this W group is a phosphorylcholine group.

[0018] [ka]

[0019] In phosphobetaine-based groups, Z may have the general formula IV:

[0020] [ka]

[0021] where A 5 is a valence bond, -O-, -S-, or -NH-, preferably -O-. R 7 is the valence bond (A 5 together with) or alkanediyl, which is -C(O)alkylene- or -C(O)NHalkylene, preferably alkanediyl, preferably containing 1 to 6 carbon atoms in the alkanediyl chain.

[0022] W 3 is S, PR 8 , or NR 8 is. This group R 8 or each group R 8 is hydrogen or alkyl of 1 to 4 carbon atoms, or two groups R 8together with the heteroatom to which they are attached form a heterocyclic ring of 5 to 7 atoms.

[0023] R 9 is an alkanediyl of 1 to 20, preferably 1 to 10, more preferably 1 to 6 carbon atoms. A 6 is a bond, NH, S or O, preferably O.

[0024] R 10 is hydroxyl, C 1~12 Alkyl, C 1~12 Alkoxy, C 7~18 Aralkyl, C 7~18 Aralkoxy, C 6~18 Aryl, or C 6~18 It is an aryloxy group.

[0025] Compounds containing a group of general formula IV can be prepared by the method described in Patent No. 3031718, in which an amino-substituted compound is reacted with a phosphorane. Preferably, the compound containing a group of general formula IV is A 5 is a bond, R 7 is a C2-6 alkanediyl, W 3 is NR 8 and each R 8 is C 1~4 is alkyl, R 9 is a C2-6 alkanediyl, A 6 is O, R 10 is C1-4 alkoxy.

[0026] In phosphobetaines, such as those having groups of formula II and II, and non-phosphobetaines, such as those having groups of formula IV, B is preferably a bond, C 1~6 branched or unbranched alkanediyl groups, such as methylene, ethylene propylene or butylene groups, or branched or unbranched C 1~6Oxyalkylene groups, such as oxymethylene, oxyethylene, oxypropylene or oxybutylene groups.

[0027] The present invention provides a means to render a wide variety of polymers radiopaque. Preferably, the polymers are hydrophilic polymers, as such polymers are generally more biocompatible.

[0028] The polymer is typically selected from the group consisting of acrylate, acrylamide, acrylic, acetal, allylic, polysaccharide, methacrylate, polyamide, polycarbonate, polyester, polyether, polyimide, polyolefin, polyphosphate, polyurethane, silicone, styrene, vinyl, or combinations and / or copolymers thereof. Preferably, the polymer comprises monomers selected from vinyl alcohol, ethylene or propylene glycol, acrylate, methacrylate, acrylamide or methacrylamide.

[0029] Exemplary hydrophilic polymers suitable for the iodinated polymer include polyvinyl alcohol, acrylates and methacrylates and their salts, carboxymethyl cellulose, hydroxyethyl cellulose, polyacrylic acid, polymethacrylic acid, polymethyl methacrylate, polyvinylpyrrolidone, polyacrylamide, polyethylene glycol (PEG), PEG-methacrylate, PEG-methyl methacrylate, tris(hydroxymethyl)methacrylamide, N,N-methylene-bis-acrylamide, chitosan, alginate, gelatin, starch, or a combination or copolymer comprising at least one of the foregoing. The polymer may be crosslinked.

[0030] In certain embodiments, the polymer comprises or is a polyhydroxylated polymer, i.e., a polymer containing repeating units with one or more pendant hydroxyls. Suitable polyhydroxylated polymers include polyol esters of acrylates and methalates, poly(hydroxyalkyl acrylates), and poly(hydroxyalkyl methacrylates), such as poly(hydroxyethyl methacrylate); poly(hydroxyalkyl acrylamides) and poly(hydroxyalkyl methacrylamides), such as tris(hydroxymethyl)methacrylamide; polymers containing vinyl alcohol, such as poly(PEG acrylates) and poly(PEG methacrylates), poly(vinyl alcohols), or (ethylene-vinyl alcohol) copolymers; polysaccharides, such as starch, chitosan, glycogen, celluloses, such as methylcellulose, alginates, and polysaccharide gums, such as carrageenan, guar, xanthan, gellan, locust bean gum, and gum arabic.

[0031] When the polymer is a polyhydroxylated polymer, G is suitably selected from ethers, esters, carbonates, carbamates, 1,3 dioxolones, and 1,3 dioxanes.

[0032] In a further embodiment, the polymer may be a polycarboxylated polymer, i.e., a polymer containing repeating units with one or more pendant carboxyl groups. These polymers include, for example, polyacrylic acid, polymethacrylic acid, and copolymers thereof. When the polymer is a polycarboxylated polymer, G is preferably selected from esters and amides.

[0033] Particularly suitable are polymers that are or comprise PVA, such as homopolymers and copolymers of PVA. One type of PVA copolymer is a polyvinyl alcohol macromer having two or more ethylenically unsaturated pendant groups per molecule, formed by the reaction of PVA with an ethylenically unsaturated monomer. PVA macromers can be formed, for example, by providing a PVA polymer with pendant vinyl or acrylic groups. Pendant acrylic groups can be provided, for example, by reacting acrylic acid or methacrylic acid with PVA to form ester bonds through some of the hydroxyl groups. Compounds containing vinyl groups capable of bonding to polyvinyl alcohol are described, for example, in U.S. Pat. No. 4,978,713, and preferably U.S. Pat. Nos. 5,508,317 and 5,583,163. Thus, a suitable macromer comprises a polyvinyl alcohol backbone attached to (alk)acrylaminoalkyl moieties. One example of such a polymer includes the PVA-N-acryloylaminoacetaldehyde (NAAADA) macromer, known as Nelfilcon-B or acrylamide-PVA.

[0034] In one preferred embodiment, the macromer can be reacted with an ethylenically unsaturated monomer, optionally bearing a positive or negative charge, such as 2-acrylamido-2-methylpropanesulfonic acid (AMPS). Such polymers and methods for making them are described in WO 04 / 071495.

[0035] When the polymer is a polyhydroxylated polymer, the group of formula 1 is preferably attached through one or more hydroxyl groups. When the polymer is a polycarboxylated polymer, the group of formula I is attached through a carboxylate group and G is preferably an ester or amide.

[0036] When the hydrophilic polymer is or comprises PVA, the polymer suitably comprises pendant groups of formula Ia or Ib, particularly 1b, pendant from the PVA.

[0037] [ka]

[0038] When G is a coupling group in which the ring is attached to the polymer through a hydroxyl group and is selected from ethers, esters, carbonates and carbamates, particularly ethers or esters, ethers being preferred.

[0039] In a particularly preferred embodiment, the polymer is a polyhydroxylated polymer that is or comprises polyvinyl alcohol, such as PVA or its copolymers, and the groups of formula I, Ia, or Ib are attached via hydroxyl groups of the polyvinyl alcohol. In another particularly preferred embodiment, the polymer is a polyhydroxylated polymer that comprises a polysaccharide and the groups of formula I are attached via cyclic or acyclic hydroxyl groups of the polysaccharide.

[0040] Polymers can be crosslinked. Crosslinks can be covalent or non-covalent. Non-covalent bonds include physical crosslinks due to entanglement of polymer chains or the presence of crystalline regions. Ionic crosslinking can occur when charged groups on a polymer are crosslinked by multivalent groups with opposite charges. In some cases, this can occur through divalent or higher metal ions such as calcium, magnesium, or barium.

[0041] Covalent crosslinking can be achieved by any of the established methods for covalently linking functional groups on different chains together. If achieved at the polymerization stage, this can be through the incorporation of bifunctional monomers. If after polymerization, through bifunctional species that can react with functional groups on the polymer, such as hydroxyl or carboxyl groups.

[0042] Crosslinkers may also introduce degradable regions (see, for example, WO 2001 / 68720) either within the crosslink molecule or at the termini. Preferably, the crosslinked polymer is a hydrogel, i.e., the polymer is water-swellable but water-insoluble. It may contain more than 50% by weight of water, preferably up to 98% by weight, preferably 60-85% by weight of water.

[0043] In addition to the optional W group, which can be charged, in a preferred embodiment, the polymer can be substituted with a group which can be charged at pH 7.4. Such groups can be positively or negatively charged and can reversibly bind to compounds of the opposite charge at physiological pH (pH 7.4). A variety of charged groups can be used, including sulfonate, phosphate, ammonium, phosphonium, and carboxylate groups. Carboxylate and sulfonate groups are preferred.

[0044] W is preferably —OH, —COOH, —SO3H, —OPO3H2, —O—(C 1~4 alkyl), -O-(C 1~4 alkyl)OH, -O-(C 1~4 alkyl)R 2 -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alkyl and -O-(C=O)C 1~4 alkyl.

[0045] And preferably, -OH, -COOH, -SO3H, -O-(C2H4O) q R 1 , -O-(C 1~4 alkyl)R 2 , -(C=O)-OC 1~4 Alkyl, -O-(C=O)C 1~4 From alkyl, more preferably -OH, -COOH, -SO3H, -O-(C2H4O) q R 1 or -O-(C 2~4 alkyl)R 2 , especially -COOH, -SO3H, -O-(C2H4O) q R 1 or -O-(C 2~4 alkyl)R 2 is selected from.

[0046] Here, -SO3H, -COOH and phenolic -OH may possibly be in the form of a pharmaceutically acceptable salt. In another approach, W can be a -BZ group, as further described below.

[0047] W is -O-(C 1~4 alkyl)R 2 In any polymer herein, which is —O—(C 2~4 alkyl)R 2 and more preferably -O-(C alkyl)R 2 or -O-(C4 alkyl)R 2 is.

[0048] X is preferably a bond or a linking group having 1 to 4 carbon atoms and optionally one heteroatom selected from O and N. More preferably, X is a bond, (C 1~4 ) alkylene, (C 1~4 ) oxyalkylene, amino (C 1~4 ) alkylene. Particular examples include a bond, C1, C2 or C3 alkylene, oxymethyl or oxyethyl, aminomethylene and aminoethylene. When a linker is present it is in particular methylene, oxymethylene or aminomethylene. Most preferably the ring is directly attached to the group G such that X is a bond.

[0049] q is preferably 1, 2, or 3. n is preferably 2 or 3, most preferably 3. R 1 is preferably H or methyl. 2 is preferably -COOH or -SO3H, especially -SO3H.

[0050] Thus, in a particularly preferred embodiment, the polymer is selected from PVA or polymers comprising PVA, and the pendant groups are of the formula:

[0051] [ka]

[0052] where W is -OH, -COOH, -SO3H, -O-(C2H4O) q R 1 or -O-(C 1~4 alkyl)R 2 , preferably -COOH, -SO3H, -O-(C2H4O) q R 1 or -O-(C 1~4 alkyl)R 2 where q is 1, 2, or 3, n is 1, 2, or 3, preferably 2 or 3, and R 1 is H or (C 1~4 alkyl), preferably methyl; R 2 is -COOH or -SO3H, but in particular -SO3H, Here, -SO3H, -COOH and phenolic -OH may possibly be in the form of a pharmaceutically acceptable salt.

[0053] In one embodiment, W is —COOH, —SO3H, —O—(C2H4O) q R 1 or -O-(C 1~4 alkyl)R 2 In particular, in the case of a polymer selected from -O-(C2H4O) q R 1 or -O-(C 1~4 alkyl)R 2 is suitable for the microspheres.

[0054] In one embodiment, the polymer comprises two or more versions of the pendant group of Formula 1, each with a different value of n. For example, there may be two, three, four, or more pendant groups, each with a different value of n.

[0055] For example, a polymer can contain pendant groups with three iodines and one iodine, or pendant groups with four iodines and one iodine, or pendant groups with two iodines and one iodine, or pendant groups with one iodine, two iodines, and three iodines. The ratio of each group can be varied to suit the desired properties. In this way, the overall hydrophobicity and iodine content / radial density of the polymer can be fine-tuned to improve physical properties such as precipitation, density, solubility, robustness of precipitate in liquid emboli, density compressibility, and drug loading into microspheres, as well as general handling and delivery characteristics of any catheter.

[0056] The ratio of one iodination value to another can be achieved by providing the appropriate ratio of iodinated phenyl moieties with the appropriate ratio for the value of n as starting materials, or by mixing polymers with pendant groups with different values of n in the appropriate ratio. Adjusting the ratio of starting materials is preferred because it avoids the separation of regions of varying hydrophobicity within the polymer.

[0057] Preferably, the polymer comprises pendant groups in which the phenyl rings are substituted in one or more of the following ways:

[0058] [ka]

[0059] Suitable rings include:

[0060] [ka]

[0061] Here, -COOH, -SO3H and phenolic -OH may be in the form of a pharmaceutically acceptable salt, such as a metal salt including sodium or potassium. As the substituted phenyl group of formula 1c, rings A to U are particularly suitable. Of these rings, H, K, L, M, N, O, R, S, T, and U are particularly suitable for microspheres.

[0062] The polymer optionally further comprises an active agent, which is preferably reversibly retained within the polymer. The agent can be reversibly bound within the polymer by ionic interactions, such as by interaction with positively or negatively charged groups on the polymer as described herein, or can be retained within the polymer by other means, such as precipitation (e.g., WO 2007 / 085615 or WO 2007 / 090897).

[0063] The active agent can be a chemotherapeutic agent, an antibody such as cetuximab, trastuzimab, and nivolumab, an antibody fragment, a peptide, a small molecular weight protein, or a combination thereof. Exemplary chemotherapeutic agents include, but are not limited to, anthracyclines such as doxorubicin, daunarubicin, epirubicin, and idarubicin; camptothecins such as irinotecan, topotecan, and exatecan; platins such as cisplatin, oxaliplatin, carboplatin, and miriplatin; antimetabolites such as mitomycin C and 5-fluorouracil; multi-tyrosine kinase inhibitors such as sorafenib, sunitinib, regorafenib, bribinb, dacetanib, bosutinib, erlotinib, gefitinib, imatinib, and vandetinib, rapamycin, or any combination thereof. If such compounds are ionizable, they can usually be used in their ionic form.

[0064] Radiopacity, or radiodensity, can be varied as needed by adjusting the amount of iodine in the polymer, which can be achieved by varying the number of iodines on the ring or by varying the ratio of pendant groups to polymer.

[0065] The polymers of the present invention are preferably 1 cm 3at least 10 mg / cm, preferably 25 mg / cm 3 , more preferably at least 50 mg / cm 3 , especially at least 100 mg / cm 3 If the polymer is water-swellable, this is measured as mg of iodine per ml of polymer fully swollen, i.e., fully hydrated, in normal saline. If the polymer is in the form of microspheres, the fully hydrated iodine content is expressed as the amount of iodine per ml of fully hydrated beads as packed volume (e.g., quantified in a graduated cylinder).

[0066] The amount of iodine in the polymer can be at least 10%, preferably at least 20%, more preferably at least 30%, and most preferably at least 35% by weight of the polymer on a dry weight basis. For these polymers, high radiodensity can be achieved when the iodine is greater than 40% by weight of the dry polymer.

[0067] Preferably, the polymers of the present invention have a radioactive density of at least 500 HU, preferably at least 1000 HU or 1500 HU, more preferably at least 2500 HU, especially at least 4000 HU, when measured at 65 kV, especially when measured according to Example 12.

[0068] The polymer may be biodegradable. The biodegradable polymer herein has bonds that are broken by hydrolysis in the body so that the polymer degrades. To provide biodegradability, the polymer may be provided with hydrolytically cleavable bonds in the human body, such as ester groups. Such bonds may occur in the backbone or, if present, in the crosslinker. The polymer may decompose into soluble components over a period of one hour to one year. Alternatively, the polymer may be non-biodegradable, so that it remains in the body in a stable form for more than one year.

[0069] The radiopaque polymers of the present invention are generally useful in the manufacture of implanted medical devices, and such devices comprising the polymers described herein provide a further aspect of the present invention. Devices include microspheres, liquid emboli, fiducial markers, tissue spacing materials, injectable bulking agents, sealants, depots for delivering active ingredients, wound dressings, and coatings on medical devices, such as those for visualization by X-ray.

[0070] One aspect of the present invention provides radiopaque polymers as described herein in the form of microspheres. While the actual size range used will depend, among other things, on clinical need, polymer microspheres typically have an average maximum diameter of up to 2000 μm. Such particles can be prepared in any subsize range required, for example, by sieving. Typical size ranges include 100-300, 300-500, 500-700, and 700-900 μm, although smaller size ranges may be advantageous in some circumstances, particularly due to their more distal embolization properties. Such smaller size ranges include 70-150 or 40-90 μm. Sizes below 20 μm are typically avoided due to off-target embolization caused by passage through capillary beds. Therefore, the practical lower limit is approximately 20-30 μm. The 40-700 μm size range is currently most commonly used in clinical applications. The polymers used can be charged as described herein so that the microspheres are suitable for loading with drugs via ionic interactions.

[0071] While the microspheres can comprise any polymer described herein, in preferred embodiments, the microspheres comprise a hydrophilic polymer, particularly a polyhydroxylated or polycarboxylated polymer described herein. In particularly preferred embodiments, the polymer is a crosslinked polyhydroxylated polymer, particularly a crosslinked polymer or copolymer of PVA described herein, particularly a macromer of Nelfilcon B reacted with an ethylenically unsaturated charged monomer, such as 2-acrylamido-2-methylpropanesulfonic acid (AMPS) or a salt thereof (e.g., sodium), as generally described in Example 1 of WO 2001 / 68720, WO 01 / 68721, and particularly WO 2004 / 071495.

[0072] A further aspect of the present invention provides liquid compositions comprising a hydrophilic polymer comprising a pendant group of Formula I. These compositions are suitable as liquid embolic compositions. Preferably, these compositions are provided as injectable liquid compositions.

[0073] Liquid embolic compositions are compositions in which the polymer is delivered to a desired site in the body as a liquid but forms an embolism in a blood vessel in vivo, particularly a composition in which the polymer gels, solidifies, or precipitates in situ to form an embolism. Such compositions typically include a hydrophilic polymer as described herein and a solvent, which may be aqueous or organic. Preferably, the composition includes a polymer of Formula 1 that completely dissolves in the solvent to form a solution of the polymer in the solvent.

[0074] Such compositions intended to precipitate at a target site within the body typically precipitate upon contact with normal saline at 20° C., and compositions in which the polymer precipitates under these conditions provide further embodiments of the invention. The radioactivity density and iodine content of these precipitates are preferably within the ranges preferred for other embodiments of the invention relating to the polymer.

[0075] It should be noted that the embolus formed typically contains voids. The values provided for suitable radiopacity (radiodensity) are for the polymer, not an average for the entire embolus.

[0076] In one approach, the hydrophilic polymer described herein can be provided as a solution in an organic solvent.Usually, such a solvent is miscible with water.Water-miscible means that 0.5ml of the solvent is completely dissolved in 1 liter of saline at 20°C.

[0077] Preferably, these solvents are biocompatible. Preferably, the solvent is a polar aprotic solvent. Preferred solvents are DMSO, DMF, DMPU (N,N'-dimethylpropylene urea), DMI (1,3-dimethyl-2-imidazolidinone), glycerol, ethyl lactate, NMP, and glycofurol (2-(oxolan-2-ylmethoxy)ethanol). In this embodiment, the solvent is preferably selected from DMSO and NMP, particularly DMSO. In one embodiment, the organic solvent may contain up to 50%, preferably up to 25%, and most preferably up to 10% water.

[0078] In another approach, the polymer of Formula 1 is dissolved in an aqueous solvent. The aqueous solvent may comprise a biocompatible organic solvent, such as those described above. Suitable solvents are selected from DMSO, DMF, DMPU (N,N'-dimethylpropylene urea), DMI (1,3-dimethyl-2-imidazolidinone), glycerol, ethyl lactate, NMP, and glycofurol (2-(oxolan-2-ylmethoxy)ethanol). Up to 50% by volume (such as up to 45%) of such solvents may be present, preferably up to 20%. The solvent is preferably selected from DMSO and NMP. However, it is preferred that the aqueous solvent does not comprise an organic solvent. In one preferred embodiment, the aqueous solvent comprises a pharmaceutically acceptable buffer. Examples of such buffers include phosphate, citrate, tromethamine, and acetate.

[0079] Preferably, the liquid composition contains 3-70% by weight of polymer, preferably at least 10% or 20%. Compositions of 5-40%, or even 5-25% dissolved polymer have useful properties, but the actual ratio of polymer to solvent will vary depending on the properties required, such as density, rate of settling, distance traveled by the polymer front, precipitate shape, and whether lava-like flow properties are present.

[0080] The polymer used in the liquid embolization is preferably one that contains vinyl alcohol, such as poly(vinyl alcohol) or ethylene-vinyl alcohol polymers and copolymers, as described herein. Optimally, the polymer is a polyvinyl alcohol homopolymer or copolymer, but preferably a PVA homopolymer.

[0081] The hydrophilic polymers described herein as liquid emboli are typically not cross-linked. Preferably, the hydrophilic polymer is a non-cross-linked PVA homopolymer or copolymer, and most preferably a non-cross-linked PVA homopolymer.

[0082] For liquid compositions, the natural PVA polymer may be acetylated or non-acetylated, typically the acetylation level of natural PVA is 50% to 100%, preferably 80% to 100%, but is 80% to 100%, typically 100%, hydrolyzed for use.

[0083] Natural PVA suitable for use in the present invention has a weight average molecular weight in the range of 1 kDa to 250 kDa, although preferably the PVA has a weight average molecular weight of at least 10 or 20 kDa, preferably at least 40 kDa. Preferred ranges include 10-250, 40-250 kDa, and 40-200 kDa.

[0084] For liquid embolism, the hydrophilic polymer may include a pendant group of formula 1a or 1b, as described above and reproduced below for ease of reference.

[0085] [ka]

[0086] When used for liquid embolization, in addition to the above preferences for general polymers or microspheres, they also include: W is preferably —OH, —COOH, —SO3H, —OPO3H2, —O—(C 1~4 alkyl)R 2 and -O-(C2H4O) q R 1 wherein -OH, -COOH, -OPO3H2 and -SO3H may be in the form of a pharmaceutically acceptable salt. W is more preferably -OH, -COOH, -SO3H or -O-(C 1~4 alkyl)R 2 is.

[0087] In one embodiment, W is —OH, —COOH, —SO3H, —OPO3H2, and —O—(C 1~4 alkyl)R 2 , preferably —OH, —O—(C 1~4 alkyl)R 2 and -COOH because they have the potential to form gels, especially in the presence of multivalent cations. This is particularly true for polymers where W is -OH. Such polymers are therefore useful, for example, for preparing gel liquid emboli, gel depots of active ingredients, gel fiducial markers, and gel-based depots of particulate medical devices and active ingredients. These are particularly relevant to the preparation of aqueous liquid emboli, and therefore a further aspect of the present invention provides an aqueous composition comprising a polymer of Formula 1. Suitable aqueous cations for forming gels with the polymer of Formula 1 include, for example, calcium, barium, magnesium, strontium, and zinc.

[0088] Thus, one embodiment of the present invention provides an aqueous composition comprising a polymer as described herein, particularly a polymer suitable for forming a gel with multivalent cations. A further embodiment provides a kit for forming a gel in vivo, comprising an aqueous composition comprising a polymer of Formula 1 and a source of multivalent cations, such as an aqueous solution.

[0089] A further aspect of the present invention provides a method of medical treatment, such as forming an embolism, comprising delivering to a blood vessel of a subject in need thereof a polymer of Formula I as described herein. The polymer may be in the form of a microsphere or other particulate, or may be a liquid embolus comprising a polymer as described herein.

[0090] If the polymer is in the form of a liquid embolus, it can be delivered in the form of a composition including a solvent, typically an organic solvent as described above, that dissipates into the bloodstream to provide the embolus, or the polymer can take the form of a composition that forms a gel within the blood vessel to form the embolus. In one embodiment, the polymers can be delivered separately, sequentially, or together with multivalent cations that cause the polymer to form a gel. The cations can be delivered in an aqueous solution. Alternatively, gelation can depend on cations present in the blood.

[0091] In a further embodiment, the present invention also provides a pharmaceutically active ingredient as described herein for use in a method of medical treatment, the treatment comprising delivering the active agent to a patient in the form of an embolic composition comprising an active agent as described herein, from which the active agent is eluted during treatment. The composition may comprise, for example, microspheres comprising the pharmaceutically active agent, or liquid emboli comprising the active agent.

[0092] The microspheres and liquid emboli described herein can be used to treat a variety of conditions, including arteriovenous malformations, gastrointestinal bleeding, aneurysm filling, and treatment of solid tumors, particularly hypervascular tumors of the liver, prostate, kidney, brain, colon, bone, lung, etc., as well as benign hyperplastic conditions such as benign prostatic hyperplasia and uterine fibroids. This approach can also be used to treat obesity and joint pain, among others.

[0093] When the composition comprises the above-mentioned active agent, such as a chemotherapeutic agent, an antibody, an antibody fragment, a peptide, a low molecular weight protein, or a combination thereof, the composition is particularly useful for treating solid tumors, especially hypervascular tumors. For example, the composition can be used to treat liver cancers, such as hepatocellular carcinoma (HCC) or distant cancer metastases, metastatic colorectal cancer, or neuroendocrine metastases.

[0094] When the polymer is a polyhydroxylated polymer, a radiopaque polymer of Formula I where G is an ester linkage can be prepared by reacting the polyhydroxylated polymer with a compound of Formula VI.

[0095] [ka]

[0096] Here, Q is a carboxylic acid, an acid halide (such as Cl or Br), or an activated carboxylic acid. When Q is a carboxylic acid, the reaction is typically carried out under acidic conditions (sulfuric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, hydrobromic acid in acetic acid, acetic acid, methanesulfonic acid, etc.) in a suitable polar solvent (DMSO, DMF, NMP, etc.).

[0097] When Q is an acid halide, the reaction is typically carried out in a suitable polar solvent (e.g., DMSO, DMF, NMP) under mildly basic conditions, for example in the presence of a mild base (e.g., pyridine, trimethylamine, lutidine, collidine or imidazole).

[0098] When Q is an activated carboxylic acid, activating agents such as carbodiimides and carbodiidazoles, e.g., DCC (N,N'-dicyclohexylcarbodiimide), EDCI (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide), and HOBt (hydroxybenzotrazol), can be used in polar aprotic solvents such as DMSO, tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, and acetonitrile. The reaction is typically carried out under anhydrous conditions in the presence of a catalytic amount of base to achieve activation. The base is usually of moderate strength (the pKa of the conjugate acid is approximately 10-13); suitable bases include various pyridines, amines, nitrogen heterocycles, triethylamine, N,N-diisopropylethylamine, DMAP, and the like.

[0099] The attachment of iodinated phenyl groups to PVA via ester bonds is discussed and exemplified, for example, in WO 2011 / 110589, WO 2014 / 152488, and Mawad et al. (2009) Biomatures, 30, 5667-5674.

[0100] To form an ether linkage, a polyhydroxylated polymer can be reacted with a compound of formula VI, where Q is a group selected from halides such as fluoride, chloride, bromide, iodide, methyl sulfonate, methyl toluene sulfonate, and trifluoromethane sulfonate. Q can be, for example, bromine.

[0101] The attachment of iodinated phenyl groups to PVA via an ether bond is described in WO 2011 / 110589. When the polymer is a polyhydroxylated polymer having 1,2 or 1,3 diol groups, radiopaque polymers of Formula I, where G is 1,3 dioxolane or 1,3 dioxane, are prepared by reacting the polyhydroxylated polymer, preferably under acidic conditions, with a compound of Formula VI, where Q is selected from groups capable of forming cyclic acetals with the diol groups. In this case, Q is preferably selected from the group consisting of aldehydes, acetals, and hemiacetals. Attaching iodinated groups to PVA in this manner is described in WO 2015 / 033092.

[0102] Polymers in which G is a carbonate linkage can be prepared by reacting a polyhydroxylated polymer with a compound of formula IV, such as formula V, in which Q is a chloroformate group.

[0103] [ka]

[0104] Polymers in which G is a carbamate linkage can be prepared by converting a polyhydroxylated polymer into a compound such as that of Formula VI, where Q is a carbamoyl chloride group, as shown in Formula IV.

[0105] [ka]

[0106] or an isocyanate group such as of formula VII:

[0107] [ka]

[0108] Both of these reactions are mediated by a weak base such as pyridine, trimethylamine, lutidine, collidine, or imidazole.

[0109] A further aspect of the present invention provides novel starting materials for preparing polymers of formula I. Accordingly, the present invention provides compounds of formula VIII:

[0110] [ka]

[0111] where: M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 alkyl, preferably R 20 and R 21 is methyl.

[0112] R 22 is H, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 alkyl or a group of formula -BZ, B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; B is preferably a bond or a C group such as a methylene, ethylenepropylene, or butylene group; 1~6 is a branched or unbranched alkanediyl group of the formula Z is a zwitterionic ammonium, phosphonium, or phosphonium phosphate or phosphonate ester group, as described in more detail herein.

[0113] R 1 is H or C 1~4 is alkyl, R 2is -COOH, -SO3H, or -OPO3H2, preferably -COOH or -SO3H, most preferably -SO3H; X is as defined above, preferably a bond; Here, -COOH, -OPO3H2, -SO3H and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0114] Preferably, R 22 is H, C 1~4 Alkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 , or -(C=O)C 1~4 alkyl or a -BZ group. More preferably, R 22 is H, -(C2H4O) q R 1 or -(C=O)C 1~4 alkyl; or a -BZ group.

[0115] However, within each of these, the -BZ group has decreasing priority. The present invention provides, inter alia, compounds of formula VIIIa:

[0116] [ka]

[0117] M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 alkyl, preferably R 20 and R 21 is methyl, optimally -CHO. 22 is H, -(C2H4O) q R 1 , or C 1~4 Alkyl-R 2 Preferably, -(C2H4O) q R 1, or C 1~4 Alkyl-R 2 , optimally C 1~4 Alkyl-R 2 , especially R 22 is (C3 or C4) alkyl-SO3H, where R 1 is H or C 1~4 alkyl, preferably -CH4; R 2 is —COOH or —SO3H, preferably —SO3H.

[0118] The present invention also provides a compound of the formula:

[0119] [ka]

[0120] where M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 alkyl, preferably R 20 and R 21 is methyl.

[0121] X is as defined above, preferably a bond; R 23 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 It is alkyl or a group of formula -BZ.

[0122] B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; B is preferably a bond or a C group such as a methylene, ethylenepropylene, or butylene group; 1~6 is a branched or unbranched alkanediyl group of the formula Z is a zwitterionic ammonium, phosphonium, or phosphonium phosphate or phosphonate ester group, as described in more detail herein.

[0123] R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, preferably -COOH or -SO3H, most preferably -SO3H; Here, -COOH, -OPO3H2, -SO3H and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0124] Preferably, R 23 is C 1~4 Alkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 alkyl or a -BZ group. More preferably, R 23 is C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 It is alkyl.

[0125] However, within each of these, the -BZ group has decreasing priority. The present invention provides in particular compounds of formula IXa:

[0126] [ka]

[0127] where: M is -CHO, -C(OH)OR 20 or -C(OH)OR 20 where R 20 and R 21 is C 1~6 alkyl, preferably R 20 and R 21 is methyl, optimally -CHO. 23 Ha-(C2H4O) q R 1 , or C 1~4 Alkyl-R 2 In particular, R 23 When C3 or C4 alkyl-SO3H is where R 1 is H or C 1~4 is alkyl, R 2 is —COOH or —SO3H, preferably —SO3H.

[0128] The present invention also provides a compound of formula X:

[0129] [ka]

[0130] where: M is -CHO, -C(OH)OR 20 OR-(C(OR 21 ) OR 20 and R 20 and R 21 is C 1~6 independently selected from alkyl, R 24 is H, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 It is alkyl or a group of formula -BZ.

[0131] B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; B is preferably a bond or a C alkylene such as a methylene, ethylenepropylene, or butylene group; 1~6 is a branched or unbranched alkanediyl group of the formula Z is a zwitterionic ammonium, phosphonium, or phosphonium phosphate or phosphonate ester group, as described in more detail herein.

[0132] R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, Here, -COOH, -OPO3H2, -SO3H and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0133] Preferably, R 24 is H, -(C2H4O) q R 1 or -(C=O)C 1~4 alkyl or a -BZ group. More preferably, R 23 is H, -(C2H4O) q R 1 or -(C=O)C 1~4 Alkyl. In particular, R 24 Ha-(C2H4O) q R 1 is.

[0134] However, within each of these, groups of formula -BZ have decreasing priority. The present invention provides, inter alia, compounds of formula Xa:

[0135] [ka]

[0136] where: M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 alkyl, preferably R 20 and R 21 is methyl, most preferably -CHO. 24 Ha-(C2H4O) q R 1 , or C 1~4 Alkyl-R 2 and especially -(C2H4O) q R 1 is.

[0137] where R 1 is H or C 1~4 is alkyl, R 2 is —COOH or —SO3H, preferably —SO3H.

[0138] The present invention also provides a compound of formula XI:

[0139] [ka]

[0140] where: M is -CHO, -C(OH)OR 20 OR-(C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, preferably methyl; R 26 and R 27 are the same or different and are -OH, -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl), -O-(C 1~4 alkyl)OH, -O-(C 1~4 alkyl)R 2, -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alkyl and -O-(C=O)C 1~4 Alternatively, W may be a zwitterionic group of formula -BZ.

[0141] Here, -SO3H, -COOH and phenolic -OH may possibly be in the form of a pharmaceutically acceptable salt. B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; B is preferably a bond or a C alkylene such as a methylene, ethylenepropylene, or butylene group; 1~6 is a branched or unbranched alkanediyl group of the formula Z is a zwitterionic ammonium, phosphonium, or phosphonium phosphate or phosphonate ester group, as described in more detail herein.

[0142] R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, Here, -COOH, -OPO3H2, -SO3H and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0143] Preferably, R 26 and R 27 are the same or different, and are -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl)R 2 , -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alternatively, W can be a zwitterionic group of formula -BZ.

[0144] More preferably, R 26and R 27 are the same or different, and are —COOH and (C═O)—OC, respectively. 1~4 alkyl. However, within each of these, groups of formula -BZ have decreasing priority.

[0145] One preferred embodiment of formula XI is a compound of the formula:

[0146] [ka]

[0147] where L is 1, 2 or 3, in particular 1; In these compounds, R 27 is —COOH or —SO3H, especially —COOH. M is -CHO, -C(OH)OR 20 OR-(C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 alkyl, preferably R 20 and R 21 is methyl, and most preferably -CHO or -C(OR 21 ) OR 20 is.

[0148] The present invention will now be further described by the following non-limiting examples with reference to the drawings, which are provided for illustrative purposes only and in light of which one skilled in the art will recognize other examples that are within the scope of the claims. All references cited herein are incorporated by reference in their entirety. In the event of a conflict between that reference and this application, this application shall control. [Effects of the Invention]

[0149] The present invention provides a polymer that is sufficiently radiopaque to be visible under X-rays. [Brief explanation of the drawings]

[0150] [Figure 1] Photographs showing a selection of microspheres of the present invention prepared according to the examples below. DETAILED DESCRIPTION OF THE INVENTION

[0151] (Example) Example 1: Synthesis of 3,5-diiodo-2-(2-(2-methoxyethoxy)ethoxy)benzaldehyde

[0152] [ka]

[0153] 3,5-Diiodosalicylaldehyde (13.9011 g, 37.72 mmol, 1.0 equiv.) and TBAI (2.7481 mg, 0.802 mmol, 0.2 equiv.) were added to a 125 ml HEL PolyBlock 8 parallel synthesis reactor equipped with a reflux condenser and a suspension magnetic stirrer. Water was added and the pH was adjusted to 9.5 with 1 M NaOH (total water volume: 97 ml). The reactor was stirred at 500 rpm until complete dissolution was achieved, resulting in a bright yellow solution. 1-Bromo-2-(2-methoxyethoxy)ethane (5.00 ml, 37.17 mmol, 1.0 equiv.) was then added. The reactor zone was set to heat at 120 °C. The reaction was monitored by thin-layer chromatography (TLC) (30% EA in i-hex), and after 2 h, additional bromide (2.50 ml, 18.59 mmol, 0.5 equiv.) was added. After another 0.5 h, the pH was readjusted to 9.5 due to consumption of bromide. After another 2 h, additional bromide (1.25 ml, 9.29 mmol, 0.25 equiv.) was added, the reactor was reduced to 50 °C, and left stirring overnight. After 19 h, the resulting suspension was reheated to reflux for 1 h, cooled to room temperature, and transferred to a separatory funnel in ethyl acetate (400 ml). The organics were washed twice with saturated sodium bicarbonate, dried over magnesium sulfate, hot filtered from toluene, and recrystallized from toluene / isohexane to give, after filtration and high vacuum drying, the desired product as a yellow powder (15.2990 g, 86.4% yield); δ H (CDCl3, 500.1MHz) / ppm;10.31(1H, s), 8.31(1H, d, 2.2Hz), 8.09(1H, d, 2.2Hz), 4.26(2H, app.t, 4.5Hz), 3.89(2H, app.t, 4.5Hz), 3.67(2H, app.t, 4.6Hz), 3.55(2H, app.t, 4.6Hz), 3.38(3H, s);δ C NMR(CDCl3, 125.8MHz) / ppm; 188.71(CH), 161.55(q), 152.43(CH), 137.57(CH), 131.75(q ), 94.07(q), 89.19(q), 75.56(CH2), 71.90(CH2), 70.79(CH2), 70.06(CH2), 59.13(CH3).

[0154] Example 2: Synthesis of 3-hydroxy-2,4,6-triiodobenzaldehyde

[0155] [ka]

[0156] A 2 L, three-necked, round-bottom flask equipped with a large, oval stir bar was charged with 3-hydroxybenzaldehyde (10.007 g, 81.89 mmol), sodium iodide (0.614 g, 4.09 mmol, 0.05 equiv.), and sodium carbonate (93.028 g, 877.44 mmol, 10.7 equiv.), rinsing with a total of 750 mL of deionized water. Once the benzaldehyde had dissolved to give a light yellow, stirring solution, iodine balls (70.008 g, 275.80 mmol, 3.37 equiv.) were added in two portions over 30 min, rinsing with 225 mL of water each time. The reaction was followed by TLC (60% DCM in i-hex), and over 3 h, the iodine had almost completely dissolved and a dark yellow / orange precipitate had formed. The solid was isolated by Buchner filtration and washed with i-hexane to remove residual iodine. The isolated solid was redissolved in warm water (2 L, 45 °C) to give 100 ml of a saturated, clear, brown solution. Sodium thiosulfate solution was added to reduce the remaining iodine. The pH of the solution was carefully lowered from 10.2 to 3.26 using 1 M HCl (beware of CO2 evolution). The solid was isolated by filtration, washed with water (2 x 500 ml), and dried in a high vacuum oven at 30 °C to give the desired compound as a yellow solid (37.002 g, 90.3% yield, 97.2% HPLC purity). H (CDCl3, 500.1MHz) / ppm;9.65(1H, s), 8.35(1H, s), 6.42(1H, s);δ C NMR (CDCl3, 125.8MHz) / ppm; 194.90(CH), 155.12(q), 149.77(CH), 135.69(q), 88.78(q), 87.66(q), 85.70(q).

[0157] Example 3: Synthesis of 2,4,6-triiodo-3-(2-(2-methoxyethoxy)ethoxy)benzaldehyde

[0158] [ka]

[0159] To a flame-dried 250 mL three-necked round-bottom flask containing a stir bar and equipped with a reflux condenser under a nitrogen atmosphere was added 3-hydroxy-2,4,6-triiodobenzaldehyde (15.627 g, 31.3 mmol, 1.0 equiv.), sodium iodide (469 mg, 3.13 mmol, 0.1 equiv.), anhydrous sodium carbonate (3.981 mg, 37.6 mmol, 1.2 equiv.), and anhydrous dimethylformamide (DMF) (160 mL). The suspension was stirred until the aldehyde was completely dissolved, and then 1-bromo-2-(2-methoxyethoxy)ethane (6.87 g, 37.5 mmol, 1.2 equiv.) was added via syringe and the reaction was heated to reflux. After 2 hours, TLC analysis (10% EA in i-hexane) indicated that the starting material had been consumed, and the reaction was cooled to room temperature, transferred to a 250 mL round-bottom flask, and evaporated to dryness under high vacuum. The resulting suspension was diluted with 500 mL of ethyl acetate, washed with 3 x 100 mL of 1 M NaOH, 2 x 100 mL of saturated brine, decolorized with activated carbon, and dried over magnesium sulfate. The resulting solution was concentrated to dryness and purified by silica column chromatography (2-20% ethyl acetate in i-hexane) and dried under high vacuum to give the desired compound as a yellow powder (7.556 g, 40.1%). H (CDCl3, 500.1MHz) / ppm;9.65(1H, s), 8.44(1H, s), 4.20(2H, t, 6.4Hz), 4.01(2H, t, 6.4Hz), 3.79(2H, app.t, 5.8Hz), 3.60(2H, app.t, 5.8H), 3.41(3H, s);δ CNMR (CDCl3, 125.8MHz) / ppm; 194.97(CH), 159.10(q), 150.83(CH), 138.27(q), 97.06(q) , 95.70(q), 90.40(q), 72.47(CH2), 72.04(CH2), 70.89(CH2), 68.89(CH2), 59.19(CH3).

[0160] Example 4: Synthesis of 2,4,6-triiodo-3(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)benzaldehyde

[0161] [ka]

[0162] Triphenylphosphine (1.7216 g, 6.502 mmol, 1.3 equiv.) and anhydrous tetrahydrofuran (THF) (35 mL) were added to a 100 mL three-necked round-bottom flask equipped with a stirrer and blanketed with nitrogen. Stirring was initiated, and after the triphenylphosphine (PPh3) was completely dissolved, the reactor was cooled to approximately 0 °C in an ice bath. To the colorless solution, diisopropyl azodicarboxylate (DIAD) (1.28 mL, 6.502 mmol, 1.3 equiv.) was added dropwise via syringe, resulting in a persistent yellow solution. After stirring for 5 minutes, triethylene glycol monomethyl ether (1.04 mL, 6.502 mmol, 1.3 equiv.) was added dropwise via syringe. After stirring for an additional 5 minutes, 3-hydroxy-2,4,6-triiodobenzaldehyde (2.5077 g, 5.002 mmol, 1.0 equiv.) was added in one portion, resulting in an immediate color change. The reaction was monitored by TLC (5% EtO in toluene) and stirred overnight. The solution was diluted with ether to precipitate triphenylphosphine oxide and then concentrated to dryness. The resulting thick oil was purified by column chromatography (2–10% EtO in toluene) to afford the desired product as a yellow powder after concentration and high vacuum drying (3.2077 g, 99% yield, 94.4% HPLC purity). H(DMSO-D6, 500.1MHz) / ppm; 9.58 (1H, s), 8.47 (1H, s), 4.08 (2H, t, 4.9Hz), 3.57~3.53 (4H, m), 3.44 (2H, app.t, 4.8Hz), 3.24 (3H, s).

[0163] Example 5: Synthesis of 3,4,5-triiodosalicyaldehyde

[0164] [ka]

[0165] A three-necked, 2 L round-bottom flask equipped with a large, oval stirrer was charged with 4-iodo-salicylaldehyde (25.01 g, 100.86 mmol, 1.0 equiv.) and acetic acid (300 mL). After stirring for 5 minutes to dissolve the solids, preheated liquid iodine monochloride (39.11 g, 2.4 equiv.) was diluted with AcOH (100 mL) and transferred to the round-bottom flask's addition funnel. This solution was added over 10 minutes. The reactor was then placed in a large silicone oil bath equipped with a 1 L addition funnel, thermometer, and condenser and set to heat to 80 °C. While heating, water (700 mL) was slowly added to the solution, causing a yellow / orange precipitate. After 20 minutes at 80 °C, the heat was turned off. After an additional 30 minutes, the heating bath was removed, and the black solution / yellow suspension was allowed to cool to room temperature and stirred for 65 hours. The reaction was analyzed by TLC (20% EA in iHex). The solid was isolated by Buchner filtration and washed with water (2 x 500 ml). To remove residual iodine crystals, the solid was repeatedly reslurried in i-hexane (200 ml) until the i-hexane supernatant was no longer purple. The isolated solid was dried overnight in a high-vac oven to give the desired product as a yellow crystalline solid (40.84 g, 81% yield, 93.2% purity by HPLC analysis). The product can be recrystallized from acetone:water (9:1) to higher purity. δ H (CDCl3, 500.1MHz) / ppm;12.15(1H, s), 9.67(1H, s), 8.09(1H, s);δ CNMR (CDCl3, 125.8MHz) / ppm; 194.53(CH), 159.58(C), 142.24(CH), 133.39(C), 120.87(C), 101.68(C), 94.02(C).

[0166] Example 6: Synthesis of 3,4,5-triiodo-2-(2-(2-methoxyethoxy)ethoxy)benzaldehyde

[0167] [ka]

[0168] (5 g scale): Triphenylphosphine (2.76 g, 10.5 mmol, 1.05 equiv.) and dry THF (70 mL) were added via syringe to a flame-dried, three-necked, 250 mL round-bottom flask containing a small octagonal stir bar under positive nitrogen pressure. The round-bottom flask was placed in a Dewar bath equipped with a low-temperature thermometer and cooled to -68 °C using an ethanol / liquid nitrogen bath. Diethyl azodicarboxylate (1.65 mL, 10.5 mmol, 1.05 equiv.) was added dropwise via syringe over 1 minute and stirred for 5 minutes to give a yellow suspension. Next, diethylene glycol monomethyl ether (1.77 mL, 15 mmol, 1.5 equiv.) was added dropwise and stirred for 5 minutes. To this, solid 3,4,5-triiodosalicyaldehyde (5.00 g, 10.0 mmol, 1.0 equiv.) was added in one portion. The initial dark orange / red suspension lightened to give a pale yellow solution, which was stirred for 2 hours, monitored by TLC analysis (20% ether in toluene), and allowed to warm to room temperature overnight. TLC indicated complete consumption of the aldehyde starting material with a clean reaction profile. The resulting solution was transferred to a 500 ml round-bottom flask, diluted with ether (200 ml), and chilled in a freezer. The resulting suspension was filtered through a short silica plug to remove triphenylphosphine oxide and further flushed with ether (200 ml). The resulting solution was concentrated to dryness and purified by column chromatography eluting with ether (2-20%) in toluene. The product fractions were concentrated to dryness and dried under high vacuum to give the desired product as a yellow amorphous solid (4.91 g, 82% yield, 96% HPLC purity); δ H δ C NMR (CDCl3, 125.8 MHz) / ppm.

[0169] Example 7: Synthesis of 5-((2,2-dimethoxyethyl)amino)-2,4,6-triiodoisophthalic acid

[0170] [ka]

[0171] To a flame-dried 500 mL round-bottom flask under nitrogen was added solid 5-amino-2,4,6-triiodoisophthalic acid (46.95 g, 84.03 mmol, 1.0 equiv.), sodium bicarbonate (28.21 g, 335.8 mmol, 4.0 equiv.), and DMF (approximately 400 mL) via cannula. To the resulting brown solution was added 2-bromo-1,1-dimethoxyethane (13 mL, 110.0 mmol, 1.3 equiv.) dropwise, and the resulting solution was heated to reflux for 18 h. After cooling to room temperature, most of the DMF was removed by rotary evaporation under vacuum (9 mBar, 55 °C), and the resulting orange solid was extracted with ethyl acetate (1 L). The suspension was washed with saturated lithium chloride solution (7 × 400 mL) to remove residual DMF and salts, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting solid was recrystallized from ethyl acetate, washed with i-hexane, and filtered. This process was repeated a total of three times, and the resulting orange solid was dried under high vacuum to give the title compound (33.04 g, 61%, 91.7% HPLC purity). The product could be further purified by silica gel column chromatography (MeOH in DCM, 0-15%) (4.91 g, 82% yield, 96% HPLC purity). H (CDCl3, 500.1MHz) / ppm;8.01(1H, s), 4.86(2H, br, s), 4.76(1H, t, 5.5Hz), 4.37(2H, d, 5.5Hz), 3.44(6H, s);δ C NMR (CDCl3, 125.8 MHz) / ppm.

[0172] Example 8: Synthesis of potassium 3-(3-formyl-2,4,6-triiodophenoxy)propane-1-sulfonate and sodium 3-(1-formyl-3,4,5-triiodophenoxy)propane-1-sulfonate

[0173] [ka]

[0174] In a 150 mL three-necked round-bottom flask, 3-hydroxy-2,4,6-triiodobenzaldehyde (10 g, 20 mmol, 1.0 equiv.) was dissolved in anhydrous THF (50 mL) using a magnetic stirrer. Potassium t-butoxide (2.47 g, 22 mmol, 1.1 equiv.) was mixed with 20 mL of THF, and the suspension was slowly added to the flask at room temperature under a nitrogen atmosphere. The temperature was then raised to 40 °C to completely dissolve the product. Next, sultone (15 g, 120 mmol, 6.0 equiv.) was dissolved in 15 mL of THF, and the mixture was slowly added to the reaction flask. A precipitate appeared immediately. After reacting at 40 °C for 3 hours, the reaction mixture was poured into 500 mL of ethyl acetate to obtain the crude solid product. The filtered solid was washed with 100 mL of ethyl acetate and recrystallized from ethanol. After drying under vacuum for 24 hours, the desired product (10.7 g, 80% yield) was isolated. H (D2O, 500.1MHz) / ppm;2.24~2.34(m, 2H), 3.12~3.25(t, 2H), 3.88~4.02(t, 2H), 8.18~8.25(s, 1H), 9.42~9.50(s, 1H)δ C NMR (CDCl3, 125.8 MHz) / ppm; elemental analysis: C 18.56, H 2.22, S 5.66, I 52.31, K 6.27. Calculated: C 18.20, H 1.22, S 4.85, I 57.68, K 5.92.

[0175] 3-(1-Formyl-3,4,5-triiodophenoxy)propane-1-sulfonate, sodium salt was synthesized similarly from 3,4,5-triiodosalicyaldehyde (Example 6).

[0176] Example 9: Preparation of microspheres Microspheres were prepared according to Example 1 of WO 2004 / 071495 (high AMPS method). The process was terminated after a step in which the product was vacuum dried to remove residual solvent. The beads were then sieved to obtain the appropriate size range. The beads were stored dry or in saline and autoclaved. Unless otherwise stated, couplings were performed on batches of microspheres with diameters between 70 and 170 μm, and reactions were performed on dry beads that were swollen in the appropriate solvent before use.

[0177] Example 10: General microsphere coupling method The desired chemical substrate (typically 0.6 equivalents relative to the PVA diol functional group), anhydrous solvent (typically dimethyl sulfoxide (DMSO) or N-methyl-2-pyrrolidone (NMP), 30 vol relative to the particle mass), and catalyst (typically 2.2 vol relative to the particle mass) were added to a pre-dried reactor under a nitrogen blanket. The solution was warmed to the reaction temperature (40–80°C) with stirring. Next, the bead particles were added, and the reactor was flushed with additional anhydrous solvent (typically 5 vol relative to the particle mass). The reaction was then stirred under a N blanket, and reaction conversion was monitored by high-performance liquid chromatography (HPLC) for consumption of the chemical substrate. At a predetermined time (typically when uptake of the chemical by the beads ceased), the stirring was turned off, and the beads were allowed to settle. The supernatant was removed by aspiration through a filter membrane, and solvent (typically 35 vol of either DMSO or 0.5 wt.% NaCl in NMP) was added and stirred for up to 10 minutes. The solvent washes were repeated for a total of five solvent washes, followed by five washes with 0.9% saline (typically 50 vol relative to particle mass). The resulting particle suspension was transferred to a 10 ml Schott vial in PBS and autoclaved at 121 °C for 30 min, then cooled to room temperature.

[0178] Example 11: Characterization of radiopaque microspheres The dry weight of the beads was measured by removing the saline solution from the packing and absorbing the remaining saline with a tissue. The beads were then vacuum dried overnight at 50°C to remove the water, from which the weight of the dried beads and the polymer solids content (wt%) were obtained. To determine the iodine level per unit volume, the settled volume of fully hydrated beads was determined, for example, using a graduated cylinder. The beads were then dried and the iodine content was determined. The iodine content of the dried beads was measured by elemental analysis using the Schoniger flask method.

[0179] Example 12: X-ray analysis of individual radiopaque beads and liquid embolic polymers MicroCT was used to evaluate the radiopacity of samples of radiopaque embolic beads prepared according to General Example 10 above. Samples were prepared in Nunc® cryotube vials (Sigma-Aldrich product code V7634, 48 mm x 12.5 mm). The beads were suspended in 0.5% agarose gel (prepared with Sigma-Aldrich product code A9539). The resulting suspension is commonly referred to as a "bead phantom." To prepare these bead phantoms, a solution of agarose (1%) is first heated to a temperature of approximately 50°C. A known amount of beads is then added, and the two are gently mixed until the solution begins to solidify or gel. As the solution cools and gels, the beads remain uniformly dispersed and suspended within the agarose gel.

[0180] Bead phantoms were tested for radiopacity using micro-computed tomography (micro-CT) with a Bruker Skyscan 1172 micro-CT scanner fitted with a tungsten anode at RSSL Laboratories, Reading, Berkshire, UK. Each phantom was analyzed using the same instrument configuration with a tungsten anode operating at a voltage of 64 kV and a current of 155 μA. Aluminum filters (500 μm) were used.

[0181] For liquid embolus samples, a two-part analysis method was used. First, an interpolated region of interest was created covering the inner diameter of the tube to include the plug and cavity structures. The image was then segmented to separate the polymer from the cavity structures and report the polymer radiodensity. The radiodensity in HU was then calculated using a water reference acquired on the same day. Table 1 lists the acquisition parameters.

[0182] [Table 1]

[0183] A small amount of purified MilliQ® water was carefully decanted into each sample tube. Each sample was then analyzed by X-ray micro-computed tomography using a single scan, including the water reference and the beads. The samples were then reconstructed using NRecon™ and calibrated against the volume of interest (VOI) of the purified water reference. To verify the Hounsfield calibration, air and water regions of interest (ROIs) were analyzed after calibration.

[0184] Radiation density was reported in Hounsfield units from line scan projections of the entire bead. Values used for the dynamic range of all samples for NRecon (threshold): -0.005, 0.13 (minimum and maximum attenuation coefficients).

[0185] Table 2 shows the radiodensity, iodine, and solids content of microspheres prepared according to general Example 10. Radiodensity data is the average of 10 line scans of an individual microsphere. Multiple microspheres were analyzed for each preparation.

[0186] [Table 2-1]

[0187] [Table 2-2]

[0188] [Table 2-3]

[0189] Example 13: Drug loading of microsphere prototypes One mL of microspheres (70-150 μm) was suspended in 1.5 mL of doxorubicin solution (concentration 25 mg / mL) under constant stirring. At predetermined time points, the supernatant solution was sampled, and the doxorubicin concentration was determined by UV at 483 nm against a known reference. Table 2 (above) shows the time to >95% loading for the microsphere prototypes. Non-radiopaque microspheres (DC Beads M1 (70-150 μm: Biocompatibles UK Ltd., UK) were loaded to >95% loading in less than 10 minutes. Commercially available radiopaque microspheres (DC Beads LUMI, Biocompatibles) with triiodophenyl groups attached to the microspheres via 1,3 dioxane groups were also loaded. UK Limited) filled to over 95% in 30 minutes.

[0190] Example 14: General liquid embolus synthesis conditions PVA (typically 5–10 g), anhydrous solvent (typically DMSO or NMP, 40 vol relative to the PVA mass), and catalyst (e.g., methanesulfonic acid, typically 2.2 vol relative to the PVA mass) are added to a pre-dried reactor under a nitrogen blanket. The stirred suspension is heated to an elevated temperature (approximately 90°C) to dissolve the PVA. Once a homogeneous solution is obtained, the mixture is cooled to the desired reaction temperature (typically 50–80°C), and the desired chemical substrate (typically 0.1–0.6 equivalents relative to the PVA diol functional group) is added. The reaction is then stirred under a nitrogen blanket, and the conversion of the reactants is monitored by HPLC for consumption of the chemical substrate. At a predetermined time (typically when consumption of the chemical substrate has stopped), anti-solvent (typically acetone, DCM, MeCN, or TBME, approximately 40 vol) is added dropwise through the addition funnel. The supernatant is removed by aspiration through a filter membrane, and additional reaction solvent (typically 40 vol) is added and stirred until the solid is completely dissolved. This solvent wash step was repeated up to three times. The solid was then redissolved in the reaction solvent and precipitated by slowly adding water (typically up to 100 vol). The resulting flocculated solid was removed from the supernatant and homogenized in an underwater blender (approximately 1 liter). The suspension was filtered, resuspended in water (typically 100 vol), slurried for up to 30 minutes, and filtered. The water slurrying was repeated until the pH was neutral, and then the wet solid was slurried in acetone (100 vol, 30 minutes of stirring, repeated twice), filtered, and dried in a high-vacuum oven at 30°C for up to 24 hours.

[0191] Example 15: Preparation of Liquid Embolism Prototype Sample prototypes are prepared in the following manner: Iodinated PVA prepared according to General Example 12 is weighed into a 10 ml vial, and the desired solvent (typically DMSO or NMP) is added to a total volume of less than 10 ml, with an overall concentration ranging from 4-20 wt%. To this, sodium hydroxide (4 M) is added at this time if necessary to create an ionic liquid embolic species. The vial containing the concentrated suspension is then sealed, placed in a sonicator, and sonicated until completely dissolved (typically for approximately 4 hours).

[0192] Example 16: Preparation of 3,4,5-triiodosalicylaldehyde (TISA)-PVA DMSO (200 ml, 67 vol) was added to a dry 600 ml HEL PolyBLOCK® vessel under a nitrogen blanket, and stirring at 500 rpm was initiated. PVA (85-124 kDa, 100% hydrolyzed, 3.0051 g) was added, rinsed into the reactor with DMSO (10 ml), and the suspension was heated to 80 °C (internal probe) until all solids dissolved. The solution was then cooled to an internal 60 °C, and 3,4,5-triiodosalicylic aldehyde (3,4,5-TISA, 6.8140 g, 13.6 mmol, 0.25 equivalents per PVA-1,3-diol unit) was charged and rinsed with DMSO (10 ml). After complete dissolution, methanesulfonic acid (6 ml, 2 vol) was added in one portion, and the reaction was stirred at 60 °C until HPLC analysis indicated that consumption of 3,4,5-TISA had ceased. The solution was cooled to room temperature and transferred to a 2 L glass breaker equipped with a large stir bar. Dichloromethane (DCM) (250 ml) and then toluene (500 ml) were added via a dropping funnel. The yellow supernatant was decanted, and the resulting solid was slowly redissolved in DMSO (150 ml) at 50 °C for 1.5 hours. The polymer was precipitated by slowly adding toluene (500 ml) and the colored supernatant was removed by in situ filtration. The polymer was redissolved in DMSO (150 ml) overnight and then precipitated by the dropwise addition of water (500 ml). The resulting solid was removed and mixed with water to obtain a uniform suspension. The pH of the solution was confirmed to be pH 7, and the solid was isolated by filtration through a Buchner funnel, washed with water (250 ml) and acetone (250 ml), and dried overnight in a high vacuum oven at 30 °C to give the desired product as a yellow / white solid (9.1517 g, 83.2 wt % yield).

[0193] Table 3 shows the yield and iodine content (w / w) of sample liquid embolic formulations prepared according to this general protocol using various molecular weight samples of PVA and TISA / PVA ratios.

[0194] [Table 3]

[0195] In a similar manner, the following commercially available aldehydes can also be conjugated to PVA: (a) 2-sulfobenzaldehyde sodium salt (Sigma-Aldrich, UK); (b) 4-formylbenzene 1,3 disulfonic acid disodium salt (Sigma-Aldrich, UK); and (c) 4-formylbenzoic acid (Sigma-Aldrich, UK).

[0196] Example 17: Precipitation of liquid emboli under flow conditions A transparent detachable tube was attached to the flow system, through which PBS was pumped using a peristaltic pump to mimic blood flow conditions. A 2.4 Fr catheter was used to deliver the liquid embolic formulation to the detachable tube. As the liquid emboli left the catheter and came into contact with PBS, they precipitated within the detachable tube. The length of the precipitate was then measured from the tip of the catheter. The flow rate and velocity drop were also recorded. The "longest distance of forward movement" was recorded. If reflux occurred, the length was recorded as the "longest distance of reflux" (cm). Table 4 documents the sedimentation characteristics of the liquid embolic formulation.

[0197] [Table 4]

[0198] Example 18: X-ray analysis of precipitated liquid emboli samples To obtain radiopacity measurements of the materials, 1 cm sections of the precipitated formulations were cut, embedded in warm (55°C) 1% agarose in polypropylene capped tubes (such as Nunc tubes), and scanned using microCT according to Example 12. Table 5 shows the radiopacity of the formulations prepared in Example 13.

[0199] [Table 5]

[0200] The technical concepts that can be understood from the above-described embodiment will be described below as supplementary notes. [Appendix 1] A hydrophilic polymer comprising a pendant group of formula I,

[0201] [ka]

[0202] where: W is -OH, -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl), -O-(C 1~4 alkyl)OH, -O-(C 1~4 alkyl)R 2 , -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alkyl and -O-(C=O)C 1~4 alkyl; or a -BZ group, wherein -OH, -COOH, -OPO3H2, and -SO3H may be in the form of a pharmaceutically acceptable salt; B is a bond or a linear or branched alkanediyl, oxyalkylene, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; Z is an ammonium, phosphonium, or sulfonium phosphate or phosphonate ester zwitterionic group; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N, and S; G is a linking group by which the group of formula I is attached to the polymer and is selected from ethers, esters, amides, carbonates, carbamates, 1,3 dioxolones, and 1,3 dioxanes; R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, q is an integer from 1 to 4, n is an integer from 1 to 4, p is an integer from 1 to 3, n+p is 2 to 5, wherein -COOH, -OPO3H2 and -SO3H, as well as the phenolic -OH, may be in the form of a pharmaceutically acceptable salt, hydrophilic polymer.

[0203] [Appendix 2] 2. The polymer of claim 1, wherein the hydrophilic polymer is a polyhydroxylated polymer and G is selected from ethers, esters, carbonates, carbamates, 1,3 dioxolones, and 1,3 dioxanes.

[0204] [Appendix 3] 2. The polymer of claim 1, wherein the hydrophilic polymer is a polycarboxylated polymer and G is selected from esters and amides.

[0205] [Appendix 4] 3. The polymer of claim 1 or 2, wherein the hydrophilic polymer is a polymer or copolymer of polyvinyl alcohol, and the group of Formula I is attached through a hydroxyl group of the polyvinyl alcohol.

[0206] [Appendix 5] 3. The polymer of claim 1 or 2, wherein the hydrophilic polymer is a homopolymer or copolymer of PVA, and the group of formula I is attached via a hydroxyl group of the polyvinyl alcohol.

[0207] [Appendix 6] comprising a group of formula Ia or Ib,

[0208] [ka]

[0209] 6. The polymer of claim 4 or 5, wherein G is a linking group that attaches the group of formula Ia to the polymer and is selected from an ether, ester, carbonate, or carbamate. [Appendix 7] 7. The polymer according to any one of claims 1 to 6, wherein n is 2 or 3.

[0210] [Appendix 8] 8. The polymer of any one of claims 1 to 7, wherein the phenyl ring of the group of formula I, Ia, or Ib is 3,5 diiodo, 3,4,5 triiodo, or 2,4,6 triiodo.

[0211] [Appendix 9] The polymer according to any one of claims 1 to 8, wherein p is 1. [Appendix 10] W is -OH, -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl), -O-(C 1~4 alkyl)OH, -O-(C 1~4 alkyl)R 2 , -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alkyl and -O-(C=O)C 1~4 alkyl; or a -BZ group, wherein B is bond, C is 1~6 A branched or unbranched alkanediyl group, or a branched or unbranched C 1~6 is an oxyalkylene group, Z is a group of formula II,

[0212] [ka]

[0213] where A 3 and A 4 are the same or different and are selected from -O, -S and -NH-; W 1+ Ha-W 2 -N + R 4 3 and W 2 is C 1~6 Alkanediyl, R 4 are the same or different, and each is hydrogen or C 1~4is alkyl, The polymer according to any one of Appendices 1 to 9, wherein -OH, COOH, -OPO3H2 and -SO3H may be in the form of a pharmaceutically acceptable salt.

[0214] [Appendix 11] W is -OH, -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl)R 2 and -O-(C2H4O) q R 1 wherein —OH, —COOH, —OPO 3 H 2 and —SO 3 H may be in the form of a pharmaceutically acceptable salt.

[0215] [Appendix 12] 12. A polymer according to any one of claims 1 to 11, wherein q is 1, 2 or 3, preferably 2 or 3.

[0216] [Appendix 13] PVA, said PVA comprising a pendant group of the formula:

[0217] [ka]

[0218] where W is -OH, -COOH, -SO3H, -O-(C2H4O) q R 1 or -O-(C 1~4 alkyl)R 2 wherein q is 1, 2, or 3, n is 1, 2, or 3, and R 1 is H or (C 1~4 alkyl), and R 2 is -COOH or -SO3H, 13. The polymer according to any one of claims 1 to 12, wherein -SO3H, -COOH and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0219] [Appendix 14] 14. A polymer according to any one of claims 1 to 13, wherein the phenyl ring of the group of formula I, Ia or Ib or 1c is substituted with one of the following formulae:

[0220] [ka]

[0221] [Appendix 15] 15. The polymer of any one of claims 1 to 14, which is crosslinked. [Appendix 16] 16. The polymer of any one of claims 1 to 15, in the form of a hydrogel containing more than 50% water by weight.

[0222] [Appendix 17] 17. The polymer of any one of claims 1 to 16, having an iodine content of greater than 10 mg per mg of dry polymer.

[0223] [Appendix 18] 1cm of fully hydrated polymer 3 15. The polymer of any one of claims 1 to 14, having an iodine content of more than 10 mg per unit area.

[0224] [Appendix 19] 15. The polymer of any one of claims 1 to 14, having a radiodensity of greater than 1000 HU.

[0225] [Appendix 20] 20. The polymer of any one of claims 1 to 19, which is substituted by a group other than W and which is charged at pH 7.4.

[0226] [Appendix 21] 21. The polymer of any one of claims 1 to 20, further comprising a pharmaceutically active ingredient. [Appendix 22] 22. A microsphere comprising a polymer of formula 1 according to any one of claims 1 to 21.

[0227] [Appendix 23] A flowable composition comprising a polymer of Formula 1 according to any one of claims 1 to 21. [Appendix 24] 22. A composition comprising a polymer of formula 1 according to any one of claims 1 to 21, in either an aqueous or organic solvent, as a water-miscible solution.

[0228] [Appendix 25] A method of treatment comprising delivering, such as by embolization, a polymer of Formula I according to any of Appendices 1-21 to a blood vessel of a patient in need thereof.

[0229] [Appendix 26] 1. An active pharmaceutical ingredient for use in a medical method, wherein the treatment comprises delivering the active pharmaceutical ingredient to a patient in the form of an embolic composition comprising the active ingredient, the active ingredient being eluted therefrom during the treatment.

[0230] [Appendix 27] Compound of Formula VIII

[0231] [ka]

[0232] where: M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, R 22 is H, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 alkyl or a group of formula -BZ; wherein B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; Z is a zwitterionic ammonium, phosphonium, or sulfonium phosphate or phosphonate ester group; R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, q is an integer from 1 to 4, X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N, and S; wherein -COOH, -OPO3H2, -SO3H and the phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0233] [Appendix 28] Formula VIIIa

[0234] [ka]

[0235] and M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, preferably methyl; R 22 is H, -(C2H4O) q R 1 , or C 1~4 Alkyl-R 2 and where R 1 is H or C 1~4 is alkyl, R 2is —COOH or —SO3H, preferably —SO3H.

[0236] [Appendix 29] A compound of formula IX,

[0237] [ka]

[0238] M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 and R 20 and R 21 is C 1~6 independently selected from alkyl, R 23 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 alkyl or a group of formula -BZ; wherein B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; Z is a zwitterionic ammonium, phosphonium, or sulfonium phosphate or phosphonate ester group; R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N, and S; wherein -COOH, -OPO3H2 and -SO3H are compounds which may be in the form of pharmaceutically acceptable salts.

[0239] [Appendix 30] Formula IXa

[0240] [ka]

[0241] where: M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, R 23 is H, -(C2H4O) q R 1 , or -(C 1~4 alkyl)-R 2 and where R 1 is H or C 1~4 is alkyl, R 2 is —COOH or —SO3H, preferably —SO3H, wherein —COOH and —SO3H may be in the form of a pharmaceutically acceptable salt.

[0242] [Appendix 31] formula

[0243] [ka]

[0244] wherein: M is -CHO, -C(OH)OR 20 OR-(C(OR 21 ) OR 20 and R 20 and R 21 is C 1~6 independently selected from alkyl, R 24 is H, C 1~4 Alkyl, C1~4 Hydroxyalkyl, C 1~4 Alkyl-R 2 , -(C2H4O) q R 1 or -(C=O)C 1~4 is alkyl or a group of formula -BZ; wherein B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; B is preferably a bond or a C group such as a methylene, ethylenepropylene, or butylene group. 1~6 and Z is a zwitterionic ammonium, phosphonium, or ester group of a phosphonium phosphate or phosphonate; R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms tp selected from O, N, and S; wherein -COOH, -OPO3H2, -SO3H and the phenolic -OH may possibly be in the form of a pharmaceutically acceptable salt.

[0245] [Appendix 32] Formula Xa

[0246] [ka]

[0247] wherein: M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, R 24Ha-(C2H4O) q R 1 , or C 1~4 Alkyl-R 2 , especially -(C2H4O) q R 1 and where R 1 is H or C 1~4 is alkyl, R 2 is —COOH or —SO 3 H, wherein —COOH and —SO 3 H may be in the form of a pharmaceutically acceptable salt.

[0248] [Appendix 33] Formula XI

[0249] [ka]

[0250] wherein: M is -CHO, -C(OH)OR 20 OR-(C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, preferably methyl; R 26 and R 27 are the same or different and are -OH, -COOH, -SO3H, -OPO3H2, -O-(C 1~4 alkyl), -O-(C 1~4 alkyl)OH, -O-(C 1~4 alkyl)R 2 , -O-(C2H4O) q R 1 , -(C=O)-OC 1~4 Alkyl and -O-(C=O)C 1~4 or alternatively, W may be a zwitterionic group of formula -BZ; wherein -SO3H, -COOH and phenolic -OH may possibly be in the form of a pharmaceutically acceptable salt; B is a bond or a linear or branched alkanediyl, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally containing one or more fluorine substituents; B is preferably a bond or a C group such as a methylene, ethylenepropylene, or butylene group; 1~6 is a branched or unbranched alkanediyl group of the formula Z is a zwitterionic ammonium, phosphonium, or phosphonium phosphate or phosphonate ester group; R 1 is H or C 1~4 is alkyl, R 2 is -COOH, -SO3H, or -OPO3H2, wherein -COOH, -OPO3H2, -SO3H and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

[0251] [Appendix 34] Formula XIa

[0252] [ka]

[0253] where L is 1, 2, or 3; R 27 is —COOH or —SO3H, preferably —COOH; M is -CHO, -C(OH)OR 20 Or-C(OR 21 ) OR 20 where R 20 and R 21 is C 1~6 independently selected from alkyl, The compound according to Appendix 33, wherein —COOH and —SO 3 H may be in the form of a pharmaceutically acceptable salt.

Claims

1. A liquid embolic composition comprising an aqueous or organic solvent and a hydrophilic polymer comprising a pendant group of formula I, 【Chemical 1】 where: W is -OH, -COOH, -SO ３ H, -OPO ３ H ２ , —O—(C １～４ alkyl), —O—(C １～４ alkyl)OH, —O—(C １～４ alkyl)R ２ , —O—(C ２ H ４ O) ｑ R １ , -(C=O)-OC １～４ Alkyl and —O—(C═O)C １～４ or a -BZ group, where -OH, -COOH, -OPO ３ H ２ and -SO ３ H may be in the form of a pharmaceutically acceptable salt; B is a bond or a linear or branched alkanediyl, oxyalkylene, alkyleneoxaalkylene, or alkylene(oligooxoalkylene) group, optionally bearing one or more fluorine substituents; Z is an ammonium, phosphonium, or sulfonium phosphate or phosphonate ester zwitterionic group; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N, and S; G is a linking group that attaches the group of formula I to the polymer and is selected from ethers, esters, amides, carbonates, carbamates, 1,3 dioxolones, and 1,3 dioxanes; R １ is H or C １～４ is alkyl, R ２ -COOH, -SO ３ H, or -OPO ３ H ２ and q is an integer from 1 to 4, n is an integer from 1 to 4, p is an integer from 1 to 3; n+p is 2 to 5; Here, -COOH, -OPO ３ H ２ and -SO ３ The liquid embolic composition, wherein H, as well as the phenolic —OH, may be in the form of a pharmaceutically acceptable salt.

2. The liquid embolic composition of claim 1, wherein the polymer is a polyhydroxylated polymer and G is selected from ethers, esters, carbonates, carbamates, 1,3 dioxolones, and 1,3 dioxanes.

3. The liquid embolic composition of claim 1, wherein the polymer is a polycarboxylated polymer and G is selected from esters and amides.

4. A liquid embolic composition as described in claim 1 or 2, wherein the polymer is a polymer or copolymer of polyvinyl alcohol and the group of formula I is attached via a hydroxyl group of the polyvinyl alcohol.

5. A liquid embolic composition as described in claim 1 or 2, wherein the polymer is a homopolymer or copolymer of PVA and the group of formula I is attached via a hydroxyl group of the polyvinyl alcohol.

6. The polymer comprises a group of formula Ia or Ib: 【Chemistry 2】 6. The liquid embolic composition of claim 4 or 5, wherein G is a linking group that connects the group of formula Ia to the polymer and is selected from ethers, esters, carbonates, or carbamates.

7. A liquid embolic composition described in any one of claims 1 to 6, wherein n is 2 or 3.

8. A liquid embolic composition described in any one of claims 1 to 7, wherein the phenyl ring of the group of formula I, Ia or Ib is 3,5 diiodo, 3,4,5 triiodo, or 2,4,6 triiodo.

9. A liquid embolic composition described in any one of claims 1 to 8, wherein p is 1.

10. W is independently selected from —OH, —COOH, —SO 3 H, —OPO 3 H 2 , —O—(C 1-4 alkyl), —O—(C 1-4 alkyl)OH, —O—(C 1-4 alkyl)R 2 , —O—(C 2 H 4 O) q R 1 , —(C═O)—O—C 1-4 alkyl, and —O—(C═O)C 1-4 alkyl; or a —BZ group, wherein B is a bond, a C 1-6 branched or unbranched alkanediyl group, or a branched or unbranched C 1-6 oxyalkylene group; Z is a group of formula II, 【Chemistry 3】 wherein A 3 and A 4 are the same or different and are selected from —O, —S and —NH—; W 1+ is —W 2 —N + R 4 3 , W 2 is C 1-6 alkanediyl; and R 4 are the same or different and each is hydrogen or C 1-4 alkyl; The liquid embolic composition according to any one of claims 1 to 9, wherein -OH, COOH, -OPO 3 H 2 and -SO 3 H may be in the form of a pharmaceutically acceptable salt.

11. A liquid embolic composition described in any one of claims 1 to 10, wherein W is selected from -OH, -COOH, -SO3H, -OPO3H2, -O-(C1-4 alkyl)R2 and -O-(C2H4O)qR1, wherein -OH, -COOH, -OPO3H2 and -SO3H may be in the form of a pharmaceutically acceptable salt.

12. A liquid embolic composition described in any one of claims 1 to 11, wherein q is 1, 2 or 3, preferably 2 or 3.

13. A polymerizable composition comprising a PVA, the PVA comprising a pendant group of the formula: 【Chemistry 4】 where W is independently selected from —OH, —COOH, —SO 3 H, —O—(C 2 H 4 O) q R 1 or —O—(C 1-4 alkyl)R 2 , where q is 1, 2, or 3, n is 1, 2, or 3, R 1 is H or (C 1-4 alkyl), and R 2 is —COOH or —SO 3 H; The liquid embolic composition according to any one of claims 1 to 12, wherein -SO 3 H, -COOH and phenolic -OH may be in the form of a pharmaceutically acceptable salt.

14. The phenyl ring of the group of formula I, Ia or Ib or 1c is substituted with one of the following formulae: 【Chemistry 5】 The liquid embolic composition according to any one of claims 1 to 13.

15. A liquid embolic composition described in any one of claims 1 to 14, having a radiodensity of greater than 1000 HU.

16. A liquid embolic composition described in any one of claims 1 to 15, wherein the polymer is substituted with a group other than W that is charged at pH 7.

4.

17. A liquid embolic composition described in any one of claims 1 to 16, further comprising an active pharmaceutical ingredient.

18. A liquid embolic composition described in any one of claims 1 to 17, wherein the solvent is an aqueous solvent.

19. A liquid embolic composition described in any one of claims 1 to 17, wherein the solvent is an organic solvent.

20. The liquid embolic composition described in Claim 19, wherein the organic solvent is an organic solvent that is miscible with water.

Images